ClinicalTrials.gg
CompletedNCT05034952Updated Dec 27, 2024Results posted

A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty

A Phase 2 interventional study of VX-548 and HB/APAP in Acute Pain, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 7 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-12-27.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
303
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing suzetrigine in Acute Pain — 3 open to participants now, 3 under way, none of them phase 3. suzetrigine · Acute Pain.

Enrollment
3rd of 10
303 · median 165
Started
2021
with 1 other
Phase 2
2 of 10
none open now
Registered
2nd of 10
by date
Lead sponsor
6 of 10
Vertex Pharmaceuticals Incorporated

Among the 10 studies testing suzetrigine in Acute Pain, this one is the 3rd largest by enrollment, is one of 2 that started in 2021, is one of 2 in phase 2, and was the 2nd registered.

Acute Pain

1,075 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

Browse Acute Pain studies →

Open to participants now

3 of the 10 studies testing suzetrigine in Acute Pain are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About suzetrigine

suzetrigine: first FDA approval 2025 (JOURNAVX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing suzetrigine in Acute Pain, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of VX-548 doses in treating acute pain after an abdominoplasty.

03

Conditions studied

  • Acute Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Before Surgery:

    • Participant scheduled to undergo an abdominoplasty without collateral procedures
  • After Surgery:

    • Participant is lucid and able to follow commands
    • All analgesic guidelines were followed during and after the abdominoplasty
    • Abdominoplasty procedure duration \<=3 hours without collateral procedures (for example., liposuction)

Key Exclusion Criteria

  • Before Surgery:

    • Prior history of abdominoplasty, intra-abdominal and/or pelvic surgery
    • History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s)
    • Any prior surgery within 1 month before the first study drug
  • After Surgery:

    • Participant had medical complications during the abdominoplasty that, in the opinion of the investigator, should preclude randomization
    • Participant had collateral procedures during the abdominoplasty

Other protocol defined Inclusion/Exclusion criteria may apply.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
303 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo matched to VX-548 and Hydrocodone bitartrate/ acetaminophen (HB/APAP) for 2 days.

    Drug: Placebo (matched to VX-548) · Drug: Placebo (matched to HB/APAP)

  • Active comparator
    HB/APAP

    Participants received HB 5 mg / APAP 325 milligrams (mg) every 6 hours (q6h) for 2 days.

    Drug: HB/APAP

  • Experimental
    VX-548: Low Dose

    Participants received VX-548 60 mg as first dose, followed by VX-548 30 mg every 12 hours (q12h) for 2 days.

    Drug: VX-548

  • Experimental
    VX-548: High Dose

    Participants received VX-548 100 mg as first dose, followed by VX-548 50 mg q12h for 2 days.

    Drug: VX-548

Interventions

  • DrugVX-548

    Tablets for oral administration.

    Also known as: Suzetrigine

  • DrugHB/APAP

    Drug pages: Hydrocodone · Acetaminophen

    Capsules for oral administration.

  • DrugPlacebo (matched to VX-548)

    Placebo matched to VX-548 for oral administration.

  • DrugPlacebo (matched to HB/APAP)

    Placebo matched to HB/APAP for oral administration.

06

What researchers measure

Primary outcomes

  1. Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) at Rest 0 to 48 Hours (SPIDr0-48) After the First Dose of Study Drug

    SPID was calculated as the sum of the product of time (in hours) elapsed since previous measurements and pain intensity difference. Pain intensity difference was calculated by subtracting the pain intensity score at given post-dose time points from the baseline pain intensity scores (using pain rating score range: 0= no pain to 10= worst possible pain). SPIDr0-48 was calculated from 0 to 48 hours and the score range was -480 (worst score) to 480 (best score).

    Time frame: 0 to 48 Hours After First Dose of Study Drug

Secondary outcomes

  1. Time-weighted SPID as Recorded on an NPRS at Rest 0 to 24 Hours (SPIDr0-24) After the First Dose of Study Drug

    SPID was calculated as the sum of the product of time (in hours) elapsed since previous measurements and pain intensity difference. Pain intensity difference was calculated by subtracting the pain intensity score at given post-dose time points from the baseline pain intensity scores (using pain rating score range: 0= no pain to 10= worst possible pain). SPIDr0-24 was calculated from 0 to 24 hours and the score range was -240 (worst score) to 240 (best score).

    Time frame: 0 to 24 Hours After First Dose of Study Drug

  2. Percentage of Participants With at Least 30 Percent (%),Reduction in NPRS (at Rest) at 48 Hours After the First Dose of Study Drug

    Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain. The percentage of participants with at least 30% reduction from baseline in NPRS at 48 hours after the first dose of VX-548 or placebo were reported.

    Time frame: From Baseline At 48 Hours After First Dose of Study Drug

  3. Percentage of Participants With at Least 50% Reduction in NPRS (at Rest) at 48 Hours After the First Dose of Study Drug

    Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0=no pain and 10=worst imaginable pain. The percentage of participants with at least 50% reduction from baseline in NPRS at 48 hours after the first dose of VX-548, HB/APAP, or placebo were reported.

    Time frame: From Baseline At 48 Hours After First Dose of Study Drug

  4. Percentage of Participants With at Least 70% Reduction in NPRS (at Rest) at 48 Hours After the First Dose of Study Drug

    Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain. The percentage of participants with at least 70% reduction from baseline in NPRS at 48 hours after the first dose of VX-548,HB/APAP or placebo were reported.

    Time frame: From Baseline at 48 Hours After First Dose of Study Drug

  5. Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 up to Day 16

07

Results

Posted Dec 27, 2024

Participant flow

Participant flow — Overall Study
MilestonePlaceboHB/APAPVX-548: Low DoseVX-548: High Dose
Started77767476
Completed75707072
Not completed2644
Withdrew: Adverse event1000
Withdrew: Withdrawal of consent (not due to ae)0210
Withdrew: Lost to follow-up1433
Withdrew: Other0001

Outcome measures

PrimaryTime-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) at Rest 0 to 48 Hours (SPIDr0-48) After the First Dose of Study Drug

SPID was calculated as the sum of the product of time (in hours) elapsed since previous measurements and pain intensity difference. Pain intensity difference was calculated by subtracting the pain intensity score at given post-dose time points from the baseline pain intensity scores (using pain rating score range: 0= no pain to 10= worst possible pain). SPIDr0-48 was calculated from 0 to 48 hours and the score range was -480 (worst score) to 480 (best score).

Time frame:
0 to 48 Hours After First Dose of Study Drug
Reported as:
Least squares mean · units on a scale
Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) at Rest 0 to 48 Hours (SPIDr0-48) After the First Dose of Study Drug
units on a scalePlaceboHB/APAPVX-548: Low DoseVX-548: High Dose
Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) at Rest 0 to 48 Hours (SPIDr0-48) After the First Dose of Study Drug72.73 ± 10.2385.20 ± 10.3095.11 ± 10.44110.53 ± 10.30
Statistical analysis
  • Placebo vs HB/APAP · ANCOVA · p = 0.3914
  • Placebo vs VX-548: Low Dose · ANCOVA · p = 0.1266
  • Placebo vs VX-548: High Dose · ANCOVA · p = 0.0097
SecondaryTime-weighted SPID as Recorded on an NPRS at Rest 0 to 24 Hours (SPIDr0-24) After the First Dose of Study Drug

SPID was calculated as the sum of the product of time (in hours) elapsed since previous measurements and pain intensity difference. Pain intensity difference was calculated by subtracting the pain intensity score at given post-dose time points from the baseline pain intensity scores (using pain rating score range: 0= no pain to 10= worst possible pain). SPIDr0-24 was calculated from 0 to 24 hours and the score range was -240 (worst score) to 240 (best score).

Time frame:
0 to 24 Hours After First Dose of Study Drug
Reported as:
Least squares mean · units on a scale
Time-weighted SPID as Recorded on an NPRS at Rest 0 to 24 Hours (SPIDr0-24) After the First Dose of Study Drug
units on a scalePlaceboHB/APAPVX-548: Low DoseVX-548: High Dose
Time-weighted SPID as Recorded on an NPRS at Rest 0 to 24 Hours (SPIDr0-24) After the First Dose of Study Drug25.96 ± 4.7029.98 ± 4.7337.65 ± 4.7945.54 ± 4.73
Statistical analysis
  • Placebo vs HB/APAP · ANCOVA · p = 0.5476
  • Placebo vs VX-548: Low Dose · ANCOVA · p = 0.0825
  • Placebo vs VX-548: High Dose · ANCOVA · p = 0.0036
SecondaryPercentage of Participants With at Least 30 Percent (%),Reduction in NPRS (at Rest) at 48 Hours After the First Dose of Study Drug

Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain. The percentage of participants with at least 30% reduction from baseline in NPRS at 48 hours after the first dose of VX-548 or placebo were reported.

Time frame:
From Baseline At 48 Hours After First Dose of Study Drug
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 30 Percent (%),Reduction in NPRS (at Rest) at 48 Hours After the First Dose of Study Drug
percentage of participantsPlaceboHB/APAPVX-548: Low DoseVX-548: High Dose
Percentage of Participants With at Least 30 Percent (%),Reduction in NPRS (at Rest) at 48 Hours After the First Dose of Study Drug48.153.959.560.5
Statistical analysis
  • Placebo vs HB/APAP · Cochran-Mantel-Haenszel · p = 0.4712
  • Placebo vs VX-548: Low Dose · Cochran-Mantel-Haenszel · p = 0.1635
  • Placebo vs VX-548: High Dose · Cochran-Mantel-Haenszel · p = 0.1158
SecondaryPercentage of Participants With at Least 50% Reduction in NPRS (at Rest) at 48 Hours After the First Dose of Study Drug

Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0=no pain and 10=worst imaginable pain. The percentage of participants with at least 50% reduction from baseline in NPRS at 48 hours after the first dose of VX-548, HB/APAP, or placebo were reported.

Time frame:
From Baseline At 48 Hours After First Dose of Study Drug
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 50% Reduction in NPRS (at Rest) at 48 Hours After the First Dose of Study Drug
percentage of participantsPlaceboHB/APAPVX-548: Low DoseVX-548: High Dose
Percentage of Participants With at Least 50% Reduction in NPRS (at Rest) at 48 Hours After the First Dose of Study Drug33.842.143.244.7
Statistical analysis
  • Placebo vs HB/APAP · Cochran-Mantel-Haenszel · p = 0.2882
  • Placebo vs VX-548: Low Dose · Cochran-Mantel-Haenszel · p = 0.2344
  • Placebo vs VX-548: High Dose · Cochran-Mantel-Haenszel · p = 0.1724
SecondaryPercentage of Participants With at Least 70% Reduction in NPRS (at Rest) at 48 Hours After the First Dose of Study Drug

Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain. The percentage of participants with at least 70% reduction from baseline in NPRS at 48 hours after the first dose of VX-548,HB/APAP or placebo were reported.

Time frame:
From Baseline at 48 Hours After First Dose of Study Drug
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 70% Reduction in NPRS (at Rest) at 48 Hours After the First Dose of Study Drug
percentage of participantsPlaceboHB/APAPVX-548: Low DoseVX-548: High Dose
Percentage of Participants With at Least 70% Reduction in NPRS (at Rest) at 48 Hours After the First Dose of Study Drug14.323.718.925.0
Statistical analysis
  • Placebo vs HB/APAP · Cochran-Mantel-Haenszel · p = 0.1343
  • Placebo vs VX-548: Low Dose · Cochran-Mantel-Haenszel · p = 0.4501
  • Placebo vs VX-548: High Dose · Cochran-Mantel-Haenszel · p = 0.1009
SecondarySafety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
Day 1 up to Day 16
Reported as:
Count of participants · Participants
Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsPlaceboHB/APAPVX-548: Low DoseVX-548: High Dose
Participants with TEAEs54464542
Participants with SAEs1110

Adverse events

Collected over Day 1 up to Day 16. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/77 (0%)1/77 (1.3%)40/77 (51.9%)
HB/APAP0/76 (0%)1/76 (1.3%)37/76 (48.7%)
VX-548 Low Dose0/74 (0%)1/74 (1.4%)37/74 (50%)
VX-548 High Dose0/76 (0%)0/76 (0%)33/76 (43.4%)
Most frequent serious events
Most frequent serious events
EventPlaceboHB/APAPVX-548 Low DoseVX-548 High Dose
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/770/761/740/76
Laryngeal stenosisRespiratory, thoracic and mediastinal disorders0/771/760/740/76
Incision site cellulitisInfections and infestations1/770/760/740/76
SepsisInfections and infestations1/770/760/740/76
Most frequent other events
Most frequent other events
EventPlaceboHB/APAPVX-548 Low DoseVX-548 High Dose
NauseaGastrointestinal disorders28/7723/7622/7414/76
DizzinessNervous system disorders14/778/7611/746/76
HeadacheNervous system disorders5/775/766/7411/76
ConstipationGastrointestinal disorders4/779/767/747/76
VomitingGastrointestinal disorders5/778/761/742/76
HyperhidrosisSkin and subcutaneous tissue disorders2/772/764/741/76
HypotensionVascular disorders3/773/764/741/76
HypoxiaRespiratory, thoracic and mediastinal disorders4/771/762/742/76

Baseline characteristics

All randomized participants who had received at least one dose of the study drug during the treatment period were included in the baseline analysis.

Age, Continuous
Age, Continuous(years)PlaceboHB/APAPVX-548: Low DoseVX-548: High DoseTotal
Mean42.6 ± 9.545.4 ± 10.741.5 ± 9.243.1 ± 9.743.2 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboHB/APAPVX-548: Low DoseVX-548: High DoseTotal
Female76737475298
Male13015
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboHB/APAPVX-548: Low DoseVX-548: High DoseTotal
Hispanic or Latino1420212580
Not Hispanic or Latino63565351223
Unknown or Not Reported00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboHB/APAPVX-548: Low DoseVX-548: High DoseTotal
White57535757224
Black or African American2018151366
American Indian or Alaska Native01012
Native Hawaiian or other Pacific Islander02024
Other02114
Multiracial00123
Pain Intensity at Baseline (at 0 hours) as Recorded on Numeric Pain Rating Scale (NPRS)
Pain Intensity at Baseline (at 0 hours) as Recorded on Numeric Pain Rating Scale (NPRS)(units on a scale)PlaceboHB/APAPVX-548: Low DoseVX-548: High DoseTotal
Mean7.4 ± 1.67.3 ± 1.87.4 ± 1.87.2 ± 1.77.3 ± 1.7
08

Study locations

7 sites
  • Arizona Research Center
    Phoenix, Arizona 85053, United States
  • Lotus Clinical Research
    Pasadena, California 91105, United States
  • Chesapeake Research Group
    Pasadena, Maryland 21122, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45417, United States
  • First Surgical Hospital
    Bellaire, Texas 77401, United States
  • Endeavor Clinical Trials
    San Antonio, Texas 78229, United States
  • JBR Clinical Research
    Salt Lake City, Utah 84107, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Dec 2021, 3 months.

Results were first posted in Dec 2024, 3 years after primary completion. A results delay was requested in Dec 2022.

Of 40 phase 2 interventional studies under Acute Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2021
First posted
Sep 5, 2021
StartActual
Aug 30, 2021
Primary completionActual
Dec 5, 2021
CompletionActual
Dec 21, 2021
Results delay requested
Dec 2, 2022
Results first posted
Dec 27, 2024
Last update
Dec 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05034952
Responsible party
Sponsor
First posted
Sep 5, 2021
Start date
Aug 30, 2021
Primary completion
Dec 5, 2021
Completion
Dec 21, 2021
Results posted
Dec 27, 2024
Last update
Dec 27, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Suzetrigine

Start the discussion